Servais Aude, Lechat Philippe, Zahr Noël, Urien Saik, Aymard Guy, Jaudon Marie Chantal, Deray Gilbert, Isnard Bagnis Corinne
Nephrology Department, Pitié-Salpêtrière University Hospital, 47 Boulevard de l'Hôpital, 75013, Paris, France.
Eur J Pharmacol. 2006 Jul 1;540(1-3):168-74. doi: 10.1016/j.ejphar.2006.04.047. Epub 2006 May 6.
Adefovir is transported by the organic anion transporter (OAT1) and the multidrug resistant protein (MRP2, 4 and 5). We studied adefovir clearance in rat after inhibition of transporters by probenecid and in mutant transport-deficient (TR-) rats, in which MRP2 is lacking. After treatment by probenecid or placebo, pharmacokinetics of adefovir 10mg/kg was studied via population nonlinear mixed effect modeling. The fraction of drug excreted in the urine was low. Renal clearance of adefovir was significantly lower (P < 0.05) in probenecid TR- rats (0.03+/-0.02l/h) than in normal control (0.09+/-0.05l/h), in normal probenecid (0.10+/-0.07l/h) and in TR- control rats (0.13+/-0.07l/h). In vivo in rats MRP2 mutation alone did not affect adefovir clearance suggesting that MRP2 does not play a critical role in the secretion of adefovir. Additional pharmacological inhibition of transporters decreased renal clearance, which may reflect inhibition of compensating transport mechanisms activated when MRP2 is lacking.
阿德福韦通过有机阴离子转运体(OAT1)以及多药耐药蛋白(MRP2、MRP4和MRP5)进行转运。我们研究了丙磺舒抑制转运体后大鼠体内阿德福韦的清除情况,以及在缺乏MRP2的转运缺陷(TR-)突变大鼠中的清除情况。在丙磺舒或安慰剂处理后,通过群体非线性混合效应模型研究了10mg/kg阿德福韦的药代动力学。经尿液排泄的药物比例较低。丙磺舒处理的TR-大鼠(0.03±0.02l/h)中阿德福韦的肾清除率显著低于正常对照(0.09±0.05l/h)、正常丙磺舒处理组(0.10±0.07l/h)以及TR-对照大鼠(0.13±0.07l/h)(P<0.05)。在大鼠体内,单独的MRP2突变并不影响阿德福韦的清除率,这表明MRP2在阿德福韦的分泌过程中不发挥关键作用。对转运体的额外药理抑制降低了肾清除率,这可能反映出当缺乏MRP2时激活的代偿性转运机制受到了抑制。